AstraZeneca’s vandetanib receives FDA acceptance in medullary thyroid cancer AstraZeneca today announced that the U.S zithromax capsules click here . Food and Medication Administration authorized the orphan medication vandetanib for the treating medullary thyroid cancers that can’t be removed by medical procedures or which has spread to other areas of your body. Vandetanib is certainly a kinase inhibitor indicated for the treating symptomatic or progressive medullary thyroid tumor in sufferers with unresectable locally advanced or metastatic disease. The usage of vandetanib in sufferers with indolent, asymptomatic or slowly progressing disease is highly recommended due to the treatment-related risks carefully.

AstraZeneca strengthens partnership with the University of Cambridge AstraZeneca, using its global biologics analysis and advancement arm together, MedImmune, offers entered into four new collaborations with the University of Cambridge, building on the existing partnership further. The agreements build on the prevailing strategic partnership between AstraZeneca, MedImmune and the University of Cambridge, with a substantial oncology analysis co-location and program of AstraZeneca researchers at the Cancer Study UK Cambridge Institute, the biggest single facility conducting tumor study in the University of Cambridge.